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COVID 19 has spread uniformly across the planet without distinction of hemispheres, 
borders, or climates. However, underdeveloped countries lack sufficient means to 
effectively detect and cope with the pandemic. The catastrophic economic situation forces 
indefinite quarantines to avoid health collapse. The scarcity of massive detection tests has 
led health personnel, the general population and their rulers to ignorance of the true 
epidemiological magnitude of SARS-CoV-2. Method: A computerized bibliographic search 
was performed using the Google search engine of original and review articles indexed by 
Scopus and WOS, in the PubMed / Medline and Cochrane databases to identify all relevant 
manuscripts and preprints, notices from professional societies and comments from 
Experts published from the start of the current epidemic related to mild COVID 19 
symptoms. Tools, massive methods for detecting the disease and their low availability in 
underdeveloped countries were analyzed. Inexpensive and easily accessible methods for 
testing for the disease were discussed. Result: According to the indexed publications on the 
incidence of hypoxemia as a symptom and parameter of the evolution of the disease, 
oxygen saturation of less than 93% was determined as the limit to consider the patient 
suspected of COVID 19. In addition, it was determined after the analysis of published 
studies show an average prevalence of anosmia-hyposmia as a mild symptom in 69% of 
patients infected with COVID 19. Conclusion: Suspected cases of COVID 19 infection could 
be detected by the presence of its prevalent signs and symptoms. More studies are needed 
to standardize and validate the postulated screening tests. 
 
Introduction 
The new pneumonia? by coronavirus denominated COVID-19 is a contagious acute systemic 
infectious disease that affects the respiratory system produced by the SARS-CoV-2 virus. Covid-19 affects 
all types of people in different ways, without gender differences and throughout the age range, in our 
experience the mean age of hospitalized patients was 65.8 years (range, 8 months-103 years) presenting a 
very disparate clinical picture (1). The “tro-ya horse” of COVID-19 is probably the large and unknown 
percentage of asymptomatic patients that would multiply their contagion power exponentially. People 
infected with COVID-19 will develop mild to moderate symptoms, a recent study of these patients reported 
85.6% and 88.0% of olfactory and gustatory dysfunctions, respectively(2). 
Symptomatic patients with coronavirus may present various associated symptoms such as fever 
with a temperature above 37.5ºC, dry cough, fatigue, myalgia, sore throat (odino-phagia), anosmia (loss of 
smell), dysgeusia (loss of taste). dyspnea (shortness of breath). In addition, some patients may experience: 
nasal congestion, runny nose (na-salt mucus), hemoptysis (expectoration of sputum with some fresh blood 
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from the respiratory system), diarrhea, nausea, vomiting, and conjunctivitis (3). But one study showed 
that 39.6% of 140 confirmed COVID-19 patients had gastrointestinal symptoms (4), and 10.1% of patients 
initially had gastrointestinal complaints (5). On average, it takes 5 to 6 days from when someone is 
infected with the virus until the first symptoms appear, however, it can take up to 14 days for them to 
appear. People with mild symptoms who are otherwise healthy should isolate themselves, and those with 
fever, cough, and shortness of breath should seek immediate medical attention (3). 
This disease was first discovered in December 2019 in the seafood market in South China, Hubei 
province, although it may have been spreading silently for years until it adopted its current lethality and 
adaptability. Currently, it was discovered that the SARS-CoV-2 virus genome is made up of a single strand 
of RNA, and is classified as a positive-stranded single-stranded RNA virus, which belongs to the genus 
Beta-coronavirus in the Coronaviridae family (6,7). This new Betacoronavirus is similar to the severe acute 
respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus 
(MERS-CoV); based on its genetic proximity, it probably originated from bat-derived coronaviruses with 
spread through an unknown intermediate mammalian host (likely wild dogs) to humans (8,9). The SARS-
CoV-2 viral genome was rapidly sequenced to allow diagnostic tests, epidemiological follow-up, and the 
development of preventive and therapeutic strategies. There are currently more than 15 million infected 
worldwide, which are not restricted by race and borders  (3,10,11). 
The cellular pathogenicity mechanism of the new coronavirus remains mysterious. COVID 19 would 
not be pneumonia in the strict sense, because the virus does not directly kill pneumocytes, but instead 
triggers an "inflammatory tsunami" (an immune reaction that attacks the cells of the respiratory system 
similar to macrophage activation syndrome) on the vascular endothelium, producing diffuse thrombosis. 
This runaway response can cause more damage to the body's own cells than to the virus it is trying to 
defeat, and it is believed to be the main reason why the conditions of young, healthy individuals can 
deteriorate rapidly (12). 
Histopathological study of the lungs of 38 deceased by Covid-19 (13), at the macroscopic level, 
showed highly congestive and edematous organs, patchy. At the histological level, it is characterized by a 
diffuse alveolar disease, which corresponds to the clinical images (radiography and computed axial 
tomography) observed in the initial and intermediate stages of the disease, with a bilateral multilobar 
pulmonary distribution. A fibrous phase is not observed, or this is rare, due to the short evolution time of 
the disease. 87% of the samples presented small thrombi (<1 mm in diameter), with a distribution greater 
than 25% of the organ in 50% of the autopsies, and in association with high levels of D-dimer in plasma, at 
the level of the alveolar light, these findings are accompanied by a large acute inflammatory component 
(14). 
These findings explain the severe hypoxemia that these patients develop, being the most serious 
complication of the disease, and support the hypothesis of associated coagulopathy and thrombosis, which 
translates or can be suspected in the face of high levels of D-dimer (15). Currently 3 possible stages of 
infection are recognized: 1st. Stage: Viral stage, mild or early infection. 2nd. Stage: Moderate stage with 
lung involvement: with hypoxia or without hypoxia. 3rd. Stage: Severe stage with systemic inflammatory 
response syndrome (16). 
In clinical practice it is very important to determine what stage each patient is at, since the 
sensitivity of the diagnostic methods (PCR and serology) depends on this, the same occurs with medical 
treatment, and antivirals may be more useful at the beginning, antimalarials, and in intermediate-final 
stages the use of corticosteroids and anti-inflammatories (17). 
According to the WHO, in 80% of patients the virus only causes a cold, but 5% of those infected 
present severe symptoms, including hyper inflammation processes, with intravascular coagulation, 
respiratory distress and cardiovascular events. The lung is the organ most affected by inflammation 
(respiratory distress), requiring in the most severe cases invasive mechanical ventilation, although the 
patient may also die from pulmonary thromboem-bolia, cardiogenic shock, septic shock, and acute cardiac 
and cerebrovascular accidents. -lar The main challenge to control this pandemic is to prevent the spread of 
the disease, where, beyond confinement, inform and educate the population, and develop the capacity and 
means to detect asymptomatic or symptomatic patients mild (18). 
Detection methods of the SARS-CoV-2 virus in a hospital setting. Specific analyzes of the viral 
genome are performed using the Polymerase Chain Reaction (PCR) and are scarce in underdeveloped 
countries. Using PCR, a fragment of genetic material is located and amplified, which in the case of the 
coronavirus is an RNA molecule. The PCR is a test that presents a degree of complexity, so it needs trained 
and prepared personnel to carry it out. It has high specificity (99.9%), since it can differentiate between 
two evolutionarily very close microorganisms and detect up to 10 copies of viral genetic material RNA, 
(Gene finder Covid-19® is the reagent used in Argentina) and is highly sensitive in the phase early 
infection. One-step reverse transcription real-time PCR is used to confirm the presence of COVID-19 by 
amplifying the virus's own RdRp, E and N genes according to the protocol recommended by the WHO. The 
93                                                                                 Garcés Villalá M.A, et all, COVID 19 Pathopyhsiology and ……. 
Copyright © 2020 Garcés Villalá M.A, Nollen, J.A, Rico, S.D, Cortez Quiroga G, Aubone de los Ríos G.O, Calvo Guirado J.L 
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. 
 
N (from the nucleocapside) is of early appearance and the last to disappear. 
A laminar flow is required for sample processing to avoid contamination to the sample and infection 
of the sample to the operator. Gloves with talc are not used because talc inhibits polymerase, nitrile 
powder-free gloves are used. 
Two dacron swabs or polyethylene microbrushes are required per patient, one nasal and one 
oropharyngeal. Both swabs are sent to the laboratory in a sterile tube with a stopper and immersed in 2 
ml of sterile physiological solution. 
A cold chain must be maintained because the genome of this virus, being RNA, is very labile. 
In addition, the samples must be homogenized trying to extract all the biological material obtained 
by the swabs, care in their preparation is crucial to avoid reporting false negative results or obtaining 
invalid tests. 
If the test detects RNA from the virus, the result is positive and SARS-CoV-2 infection is confirmed. 
Unlike PCR, rapid tests or kits for antibodies do not identify the RNA of the virus, they detect either 
antibodies produced against the virus in a blood sample, or virus proteins (antigens) present in 
respiratory samples from nasopharyngeal exudate (19). 
They are only for statistical purposes and to know if the patient had contact with this virus (20). 
There is no certain knowledge to guarantee if the presence of antibodies indicates immunity, because it is 
not yet known if the patient can be reinfected. 
Some reagents detect IgG (late-onset) antibodies, others Ig M (early-onset) or a combination of 
both. Until now the provenance of the kits speaks volumes about their sensitivity and efficiency, those of 
Chinese origin have very low sensitivities (30%), however the Korean kits are more reliable. 
In addition to speed, they present another very important advantage at the present time, since they 
can be carried out by a health professional at the home of a suspected case. These rapid diagnostic tests 
are based on a paper immunochromatography, that is, a platform that has the virus proteins 'stuck' to 
detect specific antibodies. Its operation is similar to that of pregnancy tests. This work is presented to 
postulate that a low cost and easily accessible screening test could be used in low-income countries that 
do not have massive tests to diagnose COVID 19. 
 
Method 
 A computerized bibliographic search was performed using the Google search engine of original 
and review articles indexed by Scopus and WOS, in the PubMed / Medline and Cochrane databases to 
identify all relevant manuscripts and preprints, notices from professional societies and comments from 
Experts published from the start of the current epidemic related to mild COVID 19 symptoms until August 
23, 2020. The preprint repositories included two medRxiv articles. The combined search terms included: 
"COVID-19", "SARS-CoV-2", "anosmia", "hyposmia", "hypoxia". Further searches were performed based on 
the studies that were identified (and their references). Studies were excluded if full texts could not be 
obtained. Our search identified 18 peer-reviewed articles published or accepted for publication (21–
32,32–37) and 2 manuscript preprints (not peer-reviewed) (38,39). Tools, massive methods for detecting 
the disease and their low availability in underdeveloped countries were analyzed. Inexpensive and easily 
accessible methods for testing for the disease were discussed. 
 
Result  
Early diagnosis of Covid 19. The number of asymptomatic patients with COVID 19 is perhaps 
erroneously estimated between 25 to 50%, this possibility alone undoubtedly justifies the use of 
chinstraps and frequent handwashing, although social distancing is still the best protection (40). The 
normal arterial blood oxygen saturation is 92% to 100%. Hypoxemia is an abnormal decrease in the 
partial pressure of oxygen in the arterial blood below 60 mmHg. It can also be defined as an oxygen 
saturation less than 90.7%. Patients with COVID viral pneumonia may initially (mild stage or early 
infection) have a 10% decrease in oxygen saturation (85% to 90%). This "hidden initial symptom" could 
be compensated and unfortunately silenced. with an increase in their respiratory rate. However, patients 
with COVID-19 have been found to exhibit life-incompatible oxygen levels without dyspnea. Called silent 
hypoxemia, this pathology is especially puzzling for clinicians and is considered to defy basic biology. The 
coronavirus may have an idiosyncratic action on the receptors involved in chemo-sensitivity to oxygen, but 
well-established pathophysiological mechanisms may explain most, if not all, cases of silent hypoxemia. 
These mechanisms include how dyspnea and respiratory centres respond to low levels of oxygen, how 
prevalent tensions of carbon dioxide (PaCO2) reduce the brain's response to hypoxia, the effects of disease, 
and age on the control of respiration, inaccuracy of pulse oximetry at low oxygen saturations and 
temperature-induced changes in the oxygen dissociation curve (21).                       
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Table 1. Publications related to mild symptoms of Covid 19. 
Author Publication   
date 
Mild symptom results 
Tobin MJ (21)   Aug 2020     Silent Hypoxemia (SpO2) 62%-76% 
Yan CH (22)   Apr 2020 Hyposmia-anosmia in 68% of patients 
Duca A(23)   Apr 2020 Hypoxemia (SpO2) ≤ 90% 
Dhont, S (24)  Jul 2020 Hypoxemia (SpO2) 90%-92% 
Machhi, J (25)   Jul 2020 Hypoxemia (SpO2) ≥ 90% + Hyposmia-anosmia in 36,4 
% of patients 
American Academy of Otolaryng Head 
and Neck Surg  (26) 
March 2020 Hyposmia-anosmia in 73% of patients 
 Kaye R (27)  April 2020 Hyposmia-anosmia in 73% of patients 
 Brodwin E (28) April 2020 Hyposmia-anosmia in 67% of patients 
Sedaghat AR (29)  Jul 2020 Hyposmia-anosmia in 80% of patients 
Gilani S  (30) Aug 2020 Hyposmia-anosmia in 62,5% of patients 
Spinato G (31) Apr 2020 Hyposmia-anosmia in 64,4% of patients 
Lechien JR (41) Aug 2020 Hyposmia-anosmia in 79,6% of patients 
Yan CH (33)  Jul 2020 Hyposmia-anosmia in 66,7% of patients 
Vaira LA (34)   Jul 2020 Hyposmia-anosmia in 66,7% of patients 
Van Gerven L (32)  Jun 2020 Hyposmia-anosmia in 100% of patients 
Ortiz-Prado E (35) Aug 2020 Hypoxemia (SpO2) ≤93% 
Stawicki SP (36)  May 2020 Hypoxemia (SpO2) <90% 
Xie J (37)  May 2020 Hypoxemia (SpO2) <90% 
Bagheri SHR (38)  Mar 2020 Hyposmia-anosmia in 76.2% of patients 
Haehner A (39)  Apr 2020 Hyposmia-anosmia in 64,7% of patients 
 
Using a pulse oximeter (fig. 1), a simple medical device that can be used by the same patient, this 
decrease in oxygen saturation can be identified and alerted to the suspected infection. The precision of the 
pulse oximeters is sufficient to measure saturations greater than 90%, however its accuracy decreases for 
saturations of lower percentage (42). 
 
                                              
Figure 1. Pulse oximeter indicating 73 beats per minute and 98% oxygen saturation. 
Source: Miguel Angel Garcés Villalá Copyright 2020. 
 
Two out of every three patients with COVID-19 present anosmia as the first - and only - 
manifestation of the disease, even without fever, cough or sore throat, according to studies carried out on 
more than one hundred infected people in Wuhan. Lack of smell and taste could be a clue to alert about the 
presence of COVID-19 (22). 
Olfactory dysfunction related to this disease can be severe and prolonged. Of the patients who 
reported COVID-19-associated loss of smell, 74% reported resolution of anosmia with clinical resolution 
of the disease. Infiltration of the mucosa by CD68 + macrophages expressing the viral antigen SARS-CoV-2 
may contribute to COVID-19-related olfactory dysfunction (2,22). 
According to the indexed publications on the incidence of hypoxemia as a symptom and parameter 
of the evolution of the disease, an oxygen saturation of less than 93% was determined as the limit to 
consider the patient suspected of COVID 19. In addition, it was determined after the analysis of published 
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studies show an average prevalence of anosmia-hyposmia as a mild symptom in 69% of patients infected 
with COVID 19 (22,23).  
There are two general types of methods for measuring loss of smell: objective and subjective. 
Objective measures of smell (most accurate in detecting COVID 19) encompass psychophysical tests 
designed to measure and quantify human responses to physical stimuli. Although sparingly used in COVID-
19 research to date, current psycho-physical techniques include odor threshold tests to determine the 
lowest concentration of an odour that can be detected, odour discrimination tests to measure the ability to 
differentiate between odours and odour identification tests, evaluating the ability to correctly name odour 
qualities (43). An inexpensive early detection protocol used at a United States military base in South 
Korea, where people entering the army garrison smell apple cider vinegar, could be used in Latin America. 
In Argentina, a test (olfactory test) was developed with the “scratch and smell” method, with 10 
microencapsulated fragrances (lemon, strawberry, jasmine, soap, chocolate, mandarin, vanilla, oregano, 
naphtha and eucalyptus) whose objective is use odours better known to the population and reduce 
examination costs (44). 
Screening, within the framework of health systems, refers to carrying out diagnostic tests on people, 
in principle healthy, to distinguish those who are probably ill from those who are probably not. It is a 
secondary prevention activity, the objective of which is the early detection of a certain disease in order to 
improve its prognosis and avoid premature mortality and / or the disability associated with it. In addition, 
it is possible to detect mild symptoms or situations prior to the appearance of the studied disease and its 
early treatment will reduce its incidence and morbidity. 
Screening triage by screening the suspected patient in medical and dental offices. The detection of 
oligosymptomatic patients is a challenge and a priority, to avoid the spread of the virus in crowded areas 
and at risk of confinement, such as the waiting rooms of the health system. In the health questionnaires 
(anamnesis), previous symptoms such as fever, cough, sore throat and if he had contact with patients are 
evaluated. Besides of in situ temperature control (body temperature must be less than 37 ° C) the study of 
a symptom (anosmia) and an altered physiological parameter (hypoxemia) can be used synergistically as a 
protocol and could contribute to detect suspicious cases of infection. Measurement of hypoxemia using the 
pulse oximeter and detection of anosmia using olfactory tests can be used as an initial screening test for 
the diagnosis of a suspected COVID 19 patient. These simultaneously measured parameters are enhanced 
and can detect the onset of mild symptoms. Only with one of the parameters altered is it considered a 
suspicious case. Tests are done before starting treatment. The patient who exceeds the protocol can be 
treated under strict biosafety regulations. No practice is performed in the suspected patient and the 
immediate performance of a diagnostic test for COVID 19 is suggested. 
Exams are done in the waiting room. The smell test can be carried out with coffee and vinegar 
(figure 2). To overcome triage, the patient must detect at least one of the aromas to rule out anosmia. 
Furthermore, oxygen saturation must be greater than 93% to rule out hypoxemia. 
A number of biosensors, such as pulse oximetry, can be used to track the patient's status remotely. 
In this way, it could detect patients in the early stages of disease progression and reduce the need for 
patients with mild cases to remain in medical centres for prolonged periods. 
 
                                   
                      Figure 2. Patient with closed eyes detecting coffee aroma to rule out anosmia.  
Source: Miguel Angel Garcés Villalá Copyright 2020. 
 
Discussion 
We are facing a new disease, caused by a virus with a high contagion capacity, which manifests 
clinical pictures so diverse that they range from the absence of symptoms to causing a flowery 
inflammatory condition with high mortality. The reason why early diagnosis is one of the main challenges. 
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The health and economic crisis in our environment leads us to study and understand this disease in order 
to develop simple, profitable and creative protocols, to improve the probability of suspicion and increase 
the effectiveness of diagnostic tests. 
We do not currently have effective treatment, and we are awaiting the development of a reliable 
vaccine. But we know that if treatment of complications is delayed, the inflammation prepares the ground 
for the development of respiratory distress and the formation of thrombi. 
COVID-19 causes not only lung injury but also serious cardiac complications, particularly in those 
patients with pre-existing medical conditions. Although the precise mechanism for the development of 
COVID-19-associated myocardial injury is not fully understood, a combination of direct and indirect 
pathogenic factors, such as ACE2-mediated SARS-CoV-2 infection of cardiomyocytes, hypoxia, and storm of 
cytokines, can contribute to the development of myocardial lesions and other adverse events that 
aggravate conditions and increase mortality. Close and careful monitoring of cardiac function should be 
emphasized to identify COVID-19-related myocardial injury early (45). 
The initial stage of infection is key because it is the time when the therapy could be effective. Given 
the rapid pace of scientific discoveries and clinical data generated by the large number of people quickly 
infected with SARS-CoV-2, doctors need accurate evidence on effective medical treatments for this 
infection. 
Therefore, leaving patients at home for several days with fever could aggravate the condition to a 
serious stage, increasing the risk of mortality. However, in underdeveloped countries, there are no 
available reagents with adequate sensitivity and specificity to ensure the accurate diagnosis of COVID 19 
and the few rapid tests available could give false negatives and the infected patient could continue the 
chain of infections. Longitudinal serological studies are urgently needed to determine the extent and 
duration of immunity to SARS-CoV-2. Even in the case of apparent elimination, surveillance for SARS-CoV-2 
should be maintained, as a resurgence of contagion could be possible until 2024 (46). 
The proposed screening method for early detection of disease is neither a guarantee of cure nor of 
sure success. Like all health activities it has benefits, but also adverse effects. Although there are no 
potential side effects associated with the postulated tests, patients in whom early detection does not imply 
an improvement in their prognosis will suffer a greater period of morbidity due to the diagnostic advance 
that the process itself implies. Detection of abnormalities with an uncertain prognosis or precursor lesions 
can lead to over-diagnosis and over-treatment. For these and many other reasons that could be considered, 
screening is clearly not a panacea nor is it justified in itself. A screening test must be valid, reliable, simple, 
safe and acceptable to the target population. There must be a clear consensus regarding the process of 
diagnostic confirmation and evidence that treatment in the presymptomatic phase is more effective (47). 
Some patients present severe hypoxemia in the absence of dyspnea, to reduce the risk of 
complications in such patients, a proposed solution to justify hospital admission is to control their arterial 
oxygenation by pulse oximetry at home. While the ease of use and low cost of pulse oximetry makes it an 
attractive option for identifying problems at an early stage. Counselling patients on the proper means to 
measure their oxygen saturation and when to seek assistance is essential to help ensure the successful 
implementation of the necessary monitoring programs. 
The tests postulated in this work should be standardized and evaluated in systematic studies. The 
disadvantages found are the margin of error of the oximeter apparatus and the need to calibrate the smell 
test. In addition, comparative studies will be required to contrast results with rapid tests and PCR to 
evaluate their margin of error. However, underdeveloped countries without the operational capacity to 
carry out massive tests would benefit from its implementation. The protocols must be dynamic with close 
telephone contact in symptomatic patients to detect early clinical worsening of the patient for prompt 
referral to hospital emergencies. Learning on the fly, seven months after the arrival of COVID 19, do you 
know enough or very little? Humanity until now has always been protected by nature, perhaps this 
pandemic paradoxically ends up saving our planet. 
 
Conclusions 
Suspected cases of COVID 19 infection could be detected by the presence of its prevalent signs and 
symptoms. While large methodological differences were seen in the reviewed studies, a significant 
prevalence of anosmia/hyposmia is reported in patients with COVID-19, and controlled studies indicate 
that anosmia is more common in patients with COVID-19. Additionally, oxygen saturation less than 93% 
can be used as an indicator or predictor of the course of the disease. 
The present work postulates that a low-cost screening test could be used in low-income countries 
that do not have enough tests to diagnose COVID 19.   The study of a symptom (anosmia) and a 
physiological parameter (oxygen saturation) could contribute to detecting suspected cases of SARS-COV-2 
infection. The measurement of hypoxemia using the pulse oximeter and the detection of anosmia using 
olfactory tests could be used as the initial diagnostic method for COVID 19. The advantages of 
simultaneously using the olfactory and oximetry tests are their low cost and easy access. In addition these 
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parameters synergistically they are potentiated to detect the disease in the initial stages. The 
disadvantages found are the margin of error of the pulse oximeter and the need for calibration of the 
anosmia detection method. More studies are needed to standardize and validate the postulated screening 
tests. 
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